59804-37-4 Usage
Description
Tenoxicam, a non-steroidal anti-inflammatory agent (NSAID), is a thienothiazine-derived monocarboxylic acid amide. It is structurally similar to piroxicam and the now withdrawn isoxicam. Tenoxicam is known for its effectiveness in treating pain and inflammation associated with osteoarthritis and rheumatoid arthritis. It is also used for the short-term treatment of acute musculoskeletal disorders, such as strains, sprains, and other soft-tissue injuries. Chemically, it is a yellow crystalline powder and is marketed under the brand name Tilcotil.
Uses
Used in Pharmaceutical Industry:
Tenoxicam is used as a non-steroidal anti-inflammatory agent (NSAID) for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short-term treatment of acute musculoskeletal disorders, including strains, sprains, and other soft-tissue injuries.
Used in Research and Development:
Tenoxicam is used as a standard in microanalysis of NSAIDs by spectrophotometry to test its effect on surface potential and membrane fluidity modification in phosphoglyceride monolayers. Additionally, it is used as a non-steroidal anti-inflammatory agent to study its effects on root gravitropism in Arabidopsis thaliana.
Used in Antipsychotic Applications:
Although not explicitly mentioned in the provided materials, Tenoxicam may also be used in antipsychotic applications due to its anti-inflammatory properties, which can potentially help in managing inflammation-related symptoms in certain psychiatric disorders.
Biochem/physiol Actions
Tenoxicam (TX) possesses antipyretic?and analgesic effects. It elicits radical scavenging activity and has the potential to treat enkylosing spondylitis, extra-articular diseases, acute gout, and rheumatic diseases. It is also effective in treating primary dysmenorrhea, postpartum uterine contraction pain, and post-operation backaches. TX is capable of inhibiting prostaglandin synthesis.
Clinical Use
NSAID and analgesic
Drug interactions
Potentially hazardous interactions with other drugs
ACE inhibitors and angiotensin-II antagonists:
antagonism of hypotensive effect; increased risk of
nephrotoxicity and hyperkalaemia.
Analgesics: avoid concomitant use of 2 or more
NSAIDs, including aspirin (increased side effects);
avoid with ketorolac (increased risk of side effects
and haemorrhage).
Antibacterials: possibly increased risk of convulsions
with quinolones.
Anticoagulants: effects of coumarins and
phenindione enhanced; possibly increased risk of
bleeding with heparins, dabigatran and edoxaban -
avoid long term use with edoxaban.
Antidepressants: increased risk of bleeding with
SSRIs and venlaflaxine.
Antidiabetic agents: effects of sulphonylureas
enhanced.
Antiepileptics: possibly increased phenytoin
concentration.
Antivirals: increased risk of haematological toxicity
with zidovudine; concentration possibly increased by
ritonavir.
Ciclosporin: may potentiate nephrotoxicity.
Cytotoxics: reduced excretion of methotrexate;
increased risk of bleeding with erlotinib.
Diuretics: increased risk of nephrotoxicity;
antagonism of diuretic effect; hyperkalaemia with
potassium-sparing diuretics.
Lithium: excretion decreased.
Pentoxifylline: increased risk of bleeding.
Tacrolimus: increased risk of nephrotoxicity.
Metabolism
Metabolised in the liver via cytochrome P450 2C9 to
several pharmacologically inactive metabolites (mainly
5'-hydroxy-tenoxicam).
Metabolites are excreted mainly in the urine; there is
some biliary excretion of glucuronide conjugates of the
metabolites.
Check Digit Verification of cas no
The CAS Registry Mumber 59804-37-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,9,8,0 and 4 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 59804-37:
(7*5)+(6*9)+(5*8)+(4*0)+(3*4)+(2*3)+(1*7)=154
154 % 10 = 4
So 59804-37-4 is a valid CAS Registry Number.
InChI:InChI=1/C13H11N3O4S2/c1-16-10(13(18)15-9-4-2-3-6-14-9)11(17)12-8(5-7-21-12)22(16,19)20/h2-7,17H,1H3,(H,14,15,18)
59804-37-4Relevant articles and documents
Synthesis method of tenoxicam
-
Paragraph 0026; 0027; 0028; 0029, (2017/08/30)
The invention relates to a synthesis method of tenoxicam. The synthesis method takes 3-[[N-(methoxycarbonyl)methyl]sulfonyl]-2-thiophenecarboxylate as a starting raw material and comprises the following steps: carrying out cyclization on the starting raw material to obtain a 4-hydroxy-2H-thieno[2,3-e]-1,2-thiazine-3-methyl formate1,1-dioxide intermediate; carrying out reaction on the 4-hydroxy-2H-thieno[2,3-e]-1,2-thiazine-3-methyl formate1,1-dioxide intermediate, dimethyl carbonate and 2-aminopyridine through a one-pot method to prepare the tenoxicam. A synthesis route is as follows: the synthesis route is shown in the description. The synthesis method provided by the invention has the advantages that the synthesis method has a short route and no hazardous process and is green and environmentally friendly; a final aminolysis step is avoided and raw materials react completely; the yield is more than or equal to 80 percent; the raw materials and a product are not easy to carbonize and decompose and side reaction is reduced; the product is easy to purify and the purity of the product can reach 99.85 percent; the synthesis method is a synthesis process capable of realizing industrialized production.
Preparation method of tenoxicam
-
, (2017/10/26)
The invention discloses a preparation method of tenoxicam and belongs to the technical field of medicine preparation. The preparation method comprises the following steps: using 3-chlorosulfonyl-2-thiophenecarboxylate, namely TNXK-0 as a raw material to synthesize 3-((N-(methoxycarbonyl) methyl) sulfonyl)-2-thiophenecarboxylate, namely TNXK-1; using the TNXK-1 as a raw material to synthesize 4-hydroxy-2H-thieno (2,3e)-1,2-thiazine-3-methyl formate-1,1-dioxide, namely TNXK-2; using the TNXK-2 as a raw material to synthesize 4-hydroxy-2-methyl-2H-thieno (2,3e)-1,2-thiazine-3-methyl formate-1,1-dioxide, namely TNXK-3; using the TNXK-3 and 2-aminopyridine as raw materials to synthesize the tenoxicam. The preparation method of the tenoxicam, disclosed by the invention, has the advantages of simple process, high yield and low cost; the purity of an obtained product is high.
Analogues and Derivatives of Tenoxicam. 1. Synthesis and Antiinflammatory Activity of Analogues with Different Residues on the Ring Nitrogen and the Amide Nitrogen
Binder, Dieter,Hromatka, Otto,Geissler, Franz,Schmied, Karl,Noe, Christian R.,et al.
, p. 678 - 682 (2007/10/02)
The synthesis of tenoxicam, 4-hydroxy-2-methyl-N-2-pyridyl-2H-thieno-1,2-thiazine-3-carboxamide 1,1-dioxide (1e), and of the analogues with various residues on the ring nitrogen and the amide nitrogen is described.This new class of "oxicams" has pronounced antiinflammatory and analgesic properties.The very specific structure-activity relationship of isomeric and isosteric groups at the amide nitrogen has been evaluated.The substituent in position 2 also has a great influence on the pharmacological properties.Tenoxicam is presently underrgoing clinical trials.